| 2.515 0.015 (0.6%) | 04-25 13:52 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.15 | 1-year : | 3.44 |
| Resists | First : | 2.7 | Second : | 2.95 |
| Pivot price | 2.61  |
|||
| Supports | First : | 2.29 | Second : | 1.91 |
| MAs | MA(5) : | 2.56  |
MA(20) : | 2.63 |
| MA(100) : | 2.81 |
MA(250) : | 2.29 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 39.5 |
D(3) : | 43.7 |
| RSI | RSI(14): 44 |
|||
| 52-week | High : | 3.77 | Low : | 0.96 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CLLS ] has closed above bottom band by 26.2%. Bollinger Bands are 15.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.57 - 2.59 | 2.59 - 2.6 |
| Low: | 2.45 - 2.46 | 2.46 - 2.48 |
| Close: | 2.47 - 2.5 | 2.5 - 2.52 |
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Mon, 22 Apr 2024
Cellectis Unveils Groundbreaking Gene-Editing Advances - TipRanks.com - TipRanks
Thu, 11 Apr 2024
Cellectis Unveils Gene Therapy Breakthrough - TipRanks.com - TipRanks
Mon, 08 Apr 2024
Cellectis Unveils Breakthrough Gene-Editing Innovations - TipRanks.com - TipRanks
Thu, 21 Mar 2024
IO360: first allogeneic dual CAR-T shows promise in B-cell Non-Hodgkin lymphoma - Pharmaceutical Technology
Thu, 10 Aug 2023
Cellectis to focus on CAR-T cell therapies in 2023 - Clinical Trials Arena
Tue, 22 Jun 2021
Cellectis (CLLS): FYE 2021 TALEN CAR-T Data Announcement Should Catalyse Strong Upside - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 72 (M) |
| Held by Insiders | 3.322e+007 (%) |
| Held by Institutions | 12.1 (%) |
| Shares Short | 727 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -6.282e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 257.2 % |
| Return on Equity (ttm) | -18.8 % |
| Qtrly Rev. Growth | 2.452e+007 % |
| Gross Profit (p.s.) | -4 |
| Sales Per Share | -22.78 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -66 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.12 |
| Price to Cash Flow | 5.73 |
| Dividend | 0 |
| Forward Dividend | 676480 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|